In a press release out on November 20, Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies

Inovio's SynCon(TM) Universal Flu Vaccines Provide 100% Protection in Ferrets against Death and Sickness in a Challenge Study with the Pandemic H1N1 Virus

SAN DIEGO, Nov 20, 2009 -- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets. In addition, ferrets immunized with Inovio's SynCon(TM) universal flu vaccine combinations were 100% protected against death and sickness in a challenge with the A/H1N1 (2009) swine-origin influenza. Dr. Niranjan Y. Sardesai, Inovio's SVP, Research and Development, presented this data at the Influenza Congress USA 2009 in Washington, DC, in a presentation titled, "Development of Universal SynCon(TM) DNA Vaccines for Pandemic and Seasonal Influenza."

About Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon(TM) technology enables the design of "universal" vaccines capable of protecting against multiple -- including newly emergent, unknown -- strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available atwww.inovio.com.

China Holdings Acquisition Corp. (AMEX:HOL) trading at $9.75 per share on trading volume of 24,080 shares.

In a press release out on November 20, China Holdings Acquisition Corp. Announces Approval of the Business Combination with Jinjiang Hengda Ceramics

WILMINGTON, Del., Nov 20, 2009 -- China Holdings Acquisition Corp. (AMEX:HOL) (the "Company" or "CHAC"), a special purpose acquisition company, today announced its stockholders approved the Company's previously announced proposed business combination with Success Winner Limited, CHAC's target company and the parent entity of Jinjiang Hengda Ceramics Co., Ltd. ("Hengda"). Hengda is a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings. The companies expect to consummate the business combination later today.

About China Holdings Acquisition Corp.

Founded in 2007, China Holdings Acquisition Corp. ("CHAC") is a blank check company focused on acquiring companies with primary operations in Asia through a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination or contractual arrangements. CHAC currently has no operating businesses

Franklin Street Properties Corp. (NYSE Amex: FSP) trading at $10.86 on a volume of 157,595 shares

In a press release out on November 20, Franklin Street Properties Corp. Achieves the First Existing Buildings: Operations & Maintenance Leed(R) Certification in the State of Indiana

WAKEFIELD, MA, Nov 20, 2009 -- Franklin Street Properties Corp. ("FSP", "we", "our" or "its") (NYSE Amex: FSP), an investment firm specializing in real estate, today announced that its office buildings located at 3815 and 3925 River Crossing Parkway, Indianapolis, Indiana, have received LEED Silver Certification by the U.S. Green Building Council ("USGBC") in the Leadership in Energy and Environmental Design ("LEED") for Existing Buildings: Operations & Maintenance ("LEED-EB: O&M").

About Franklin Street Properties Corp.

Franklin Street Properties Corp., based in Wakefield, Massachusetts, is focused on achieving current income and long-term growth through investments in commercial properties. FSP operates in two business segments: real estate operations and investment banking/investment services. The majority of FSP's property portfolio is suburban office buildings, with select investments in certain central business district properties. FSP's subsidiary, FSP Investments LLC (member, FINRA and SIPC), is a real estate investment banking firm and a registered broker/dealer. FSP is a Maryland corporation that operates in a manner intended to qualify as a real estate investment trust (REIT) for federal income tax purposes. To learn more about FSP please visit our website atwww.franklinstreetproperties.com.

Crosshair Exploration & Mining Corp. (TSX:CXX)(NYSE Amex:CXZ) trading at $0.208 on a volume of 31,900 shares

In a press release out on November 20, Crosshair Closes Concurrent Private Placements for Gross Proceeds of $2,275,000

VANCOUVER, BRITISH COLUMBIA, Nov 20, 2009 -- Crosshair Exploration & Mining Corp. (TSX:CXX)(NYSE Amex:CXZ) ("Crosshair") is pleased to announce the closing on November 19, 2009 of a brokered private placement with Byron Securities Limited (the "Agent") of 5,000,000 units (the "Units") to Canadian accredited investors at a price of $0.20 per Unit for gross proceeds of $1,000,000 (the "Unit Private Placement"). Each Unit consists of one common share in the capital of Crosshair (a "Common Share") and one common share purchase warrant (a "Warrant") with each Warrant exercisable for one Common Share at an exercise price of $0.30 per Common Share for 24 months from November 19, 2009.

About Crosshair

Crosshair is a dominant player in the exploration and development of uranium and gold in the US and Canada. Its flagship Project, Bootheel, is located in uranium mining friendly Wyoming and with its in-situ mining potential, Bootheel is designed for near term production. The CMB Uranium Project is located in Labrador, Canada and has four currently defined resources - C Zone, Area 1, Armstrong and Two Time Zone. The Crosshair team is comprised of knowledgeable and experienced professionals with both exploration and mining backgrounds.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.